In its most recent Form 13F filing with the SEC, AlphaQuest LLC disclosed a 1,038.0% increase in its holding of ResMed Inc. shares during the third quarter. The firm acquired an additional 14,013 shares, bringing its total position to 15,363 shares by period end. At quarter close, these holdings carried a notional value of approximately $4.205 million. This sizeable purchase underscores AlphaQuest’s conviction in ResMed’s growth prospects within the sleep and respiratory care market.

Several other institutional investors also adjusted their ResMed positions in the latest quarter. SJS Investment Consulting increased its stake by 1,433.3%, now owning 92 shares valued at roughly $25,000. WFA of San Diego initiated a new position worth about $26,000, while GoalVest Advisory entered with $37,000 in shares. Harbour Investments raised its holding by 264.2% to 244 shares (approximately $63,000), and Root Financial Partners established a new stake around $64,000. Collectively, hedge funds and institutions now control 54.98% of ResMed’s outstanding shares.

On January 29, ResMed reported quarterly earnings of $2.81 per share, topping consensus estimates by $0.13 and representing a 15% year-over-year increase. Revenue for the period reached $1.42 billion, exceeding forecasts by $20 million and reflecting an 11% increase compared to the prior year. The company achieved a net margin of 27.35% and a return on equity of 25.45%, driven by manufacturing efficiencies and robust demand for its CPAP and digital health solutions.

Equity analysts remain broadly positive on ResMed’s outlook. Among those covering the stock, one has issued a Strong Buy rating, eight maintain a Buy, and six recommend Hold. The consensus target price stands at approximately $296.09. Analysts cite ResMed’s expanding digital health ecosystem across 140 countries, continued gross margin expansion, and double-digit EPS growth as key drivers for sustained value creation.